Intervention not reported
mg/day LDL cholesterol · participants with normal or abnormal lipid profiles
The intervention showed no clear difference in mg/day LDL cholesterol (high certainty).
1 finding from 1 review
Intervention not reported
Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
WDAEs · participants with normal or abnormal lipid profiles
It is very uncertain whether the intervention changes WDAEs (very low certainty).
1 finding from 1 review
Underweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
Standard‐protein formula showed no clear difference in adverse events compared with low‐protein formula (low certainty).
1 finding from 1 review
Stunting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes overweight compared with standard‐protein formula (very low certainty).
1 finding from 1 review
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes obesity compared with standard‐protein formula (very low certainty).
1 finding from 1 review
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
High‐protein formula showed no clear difference in adverse events compared with standard‐protein formula (low certainty).
1 finding from 1 review
Underweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Stunting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Intraoperative blood loss (mL) · people with PAD undergoing MLLA
1 finding from 1 review
Fall in haemoglobin levels(g/L or mmol/L) ( · people with PAD undergoing MLLA
1 finding from 1 review
Blood transfusion · people with PAD undergoing MLLA
1 finding from 1 review